QL Biopharm
PrivateLast Round
Series C
Mar 2, 2026
Est. Valuation
$417.5M
Total Funding Raised
$158.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
QL Biopharm is a biotechnology company that develops innovative drugs for chronic metabolic diseases such as obesity, diabetes, and non-alcoholic fatty liver disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
QL Biopharm Comparables
Compare QL Biopharm with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sciwind Biosciences | 85% | |
| PegBio Co Ltd | 81% | |
| Gmax Biopharm | 80% |
QL Biopharm Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Mar 2, 2026 | ||||
| Series C | Feb 17, 2025 | ||||
| Series B Extension | Nov 27, 2023 | ||||
| Series B | Mar 6, 2023 | ||||
| Series B | Feb 15, 2022 | ||||
Series A | Oct 27, 2020 |
QL Biopharm Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Lanchi Ventures | Series B Extension, Series B |
| BioTrack Capital | Series A |
| TF Capital | Series C |
| Jiyuan Capital | Series B Extension |
| Tigeryeah Capital | Series C, Series A |
| OrbiMed | Series C |
| 中国风险投资有限公司 | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 2, 2026
$72M round led by OrbiMed
- Nov 27, 2023
$28M round led by China-US Green Fund and Imeik Technology.
QL Biopharm Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about QL Biopharm's valuation, stock price, and market status.
Is QL Biopharm a public or private company?
QL Biopharm is a private company.
What is the current stock price of QL Biopharm?
QL Biopharm is a private company with no public stock price. No recent secondary market data is available.
How much is QL Biopharm worth (valuation)?
Valuation information for QL Biopharm is not publicly available.
Can I buy QL Biopharm stock?
QL Biopharm shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was QL Biopharm's last funding round?
QL Biopharm's most recent funding round was Series C on March 2, 2026.
Who are the main investors in QL Biopharm?
Key investors in QL Biopharm include OrbiMed, 中国风险投资有限公司, BlueRun Ventures, China-US Green Fund, HongShan.
Will QL Biopharm IPO soon?
No public IPO plans have been announced for QL Biopharm.
How can I track QL Biopharm secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor QL Biopharm's secondary market activity and sign up for updates.